We have previously shown that a dual system for controlling gene expression that relies both on transcriptional regulation and DNA recombination mediated by the site-directed recombinase, Flp, effectively controls the expression of a gene encoding diphtheria toxin (DT-A). In this study, we investigated the use of a chimeric modified enhancer/ promoter sequence of the human prostate-specific antigen (PSA) gene to regulate DT-A expression in human prostate cancer cells in culture, in xenografts derived from these cells, and in autochthonous tumors in TRAMP mice. Following adenoviral delivery of DNA encoding PSA promoter-driven Flp recombinase and DT-A, we demonstrate that this transcriptional/DNA recombination control strategy effectively activates DT-A expression in a manner that correlates with the amount of PSA and androgen in cells. Significantly, the size of xenografts was reduced by 50%, and tumor cells in TRAMP mice died following intratumoral injection of DT-A viruses. Direct injection of virally-delivered DT-A into normal mouse prostates resulted in a dramatic reduction in the size of the gland. Our results suggest that the PSA promoterdriven Flp recombinase regulatory system will allow for targeted death of PSA-expressing cells. When combined with newly developed strategies for targeted gene delivery, this approach holds promise as an effective systemicallyadministered therapy for metastatic prostate cancer. Gene Therapy (2005) 12, 1573-1580.
Introduction
Prostate cancer is the second leading cause of cancer deaths of American men. 1 The high incidence of prostate cancer deaths is attributable to the fact that many patients have metastatic disease at the time of disease presentation. While surgery and radiation are often used successfully to treat the primary tumor, albeit often with significant unwanted side effects, there is currently no effective cure for metastatic prostate cancer. Hormone ablation therapy only effectively treats androgen-dependent tumors, while chemotherapy lacks tumor-specificity and administration of effective doses is limited by toxicity issues.
Systemic delivery of genes that encode cellular toxins is an alternative therapy that holds great promise for improving our ability to treat metastatic prostate cancer effectively. Targeted expression of diphtheria toxin (DT), resulting in the death of prostate cancer cells, is an attractive therapeutic option because the mechanism of action of this toxin is known, 2 and the DT gene has been cloned, sequenced, and adapted for expression in mammalian cells. Naturally occurring DT is made by Corynebacterium diphtheriae as a secreted precursor polypeptide that is then enzymatically cleaved into two fragments, the A and B chains. The B chain binds to the surface of most eukaryotic cells and then delivers the A chain (DT-A) into the cytoplasm. Once inside the cell, DT-A inhibits protein synthesis, resulting in cell death. A DT gene, engineered for use in mammalian cells, DT-A, encodes DT-A, but not DT-B. 3 In the absence of DT-B, even DT-A released from dead cells is not able to enter other neighboring cells, thereby ensuring that the toxin only kills targeted cells.
We have previously described a novel strategy aimed at expressing DT-A in androgen-independent prostate cancer cells. This strategy relied on both transcriptional regulation and regulated DNA recombination mediated by a site-directed DNA recombinase enzyme, Flp recombinase, to control expression of this very potent toxin. 4 In that study, we used a sequence upstream of the human BCL2 gene containing the promoter and other regulatory elements to activate DT-A expression in androgenindependent tumor cells. While this study demonstrated the utility of this approach for regulating the expression of a very toxic protein, the fact that BCL2 regulatory elements direct expression to other cell types, in addition to the tumor cells that we wish to target, is a serious drawback to their practical use. BCL2 promoter-regulated therapy for metastatic prostate cancer would result in unwanted cell death and probable deleterious consequences.
In this report, we improve our strategy and use a chimeric modified enhancer/promoter sequence of the human prostate-specific antigen (PSA) gene, PSE-BC, 5 to regulate the expression of Flp recombinase. Upon DNA recombination, DT-A is expressed. PSE-BC retains discriminatory capabilities, so DT-A is targeted to cells that normally express PSA, that is, luminal cells in the epithelium of the normal prostate and prostate cancer cells in primary and metastatic tumors, irrespective of their dependency on androgen.
Using adenoviral vectors to deliver DNA, we assessed the capacity of this PSA promoter-driven transcriptional/DNA recombination regulatory strategy to activate DT-A expression in human PSA-expressing prostate tumor cells in culture and in xenografts derived from these cells. In additional experiments, we virally infected normal, nontumorigenic prostate cells in mice and prostate tumor cells in TRAMP mice, a transgenic mouse model for prostate cancer. Our results demonstrate that PSA promoter-driven, tightly regulated expression of DT-A effectively kills normal prostate and prostate cancer cells. A transcriptionally based strategy, such as the one described here to target DT-A expression, used in combination with new ways to target the delivery to tumor cells via vector modifications, holds promise as an effective therapy for the treatment of metastatic cancer.
Results

Overall strategy and DNA constructs
We used a Flp recombinase-mediated gene activation system to regulate the expression of DT-A. 4 Flp recombinase expression was controlled by a chimeric modified enhancer/promoter sequence of the human PSA gene, PSE-BC, 5 henceforth referred to simply as the PSA promoter. This transcriptional regulation combined with Flp recombinase-mediated DNA recombination was used to safeguard against expression of DT-A in non-PSA-expressing cells. The DNA constructs that were used in this study, including constructs in which the DT-A sequence is replaced by reporter protein sequences (LacZ, firefly luciferase, and green fluorescent protein (EGFP)) are shown in Figure 1 . All DNA sequences were housed in an adenoviral vector, serotype 5.
Correlation of PSA promoter-driven Flp recombinasemediated gene expression with amounts of PSA protein and androgen
To test whether the amount of Flp recombinase-mediated gene expression driven by the PSA promoter corresponds to the amount of PSA produced by cells, we infected cells from two human prostate cancer cell lines, PC-3 and LNCaP, known to differ in their expression of PSA. LNCaP cells express PSA at a high level compared to PC-3 cells. In this experiment, we infected cells with Ad-PSA/ FLP (multiplicity of infection (moi) ¼ 100) and varying amounts of Ad-RSV/FRT2neo/EGFP (moi ¼ 10, 20, and 50). At 48 h postinfection, 10-55% more LNCaP cells expressed EGFP than did PC-3 cells (Figure 2b ). Higher infectivity of both cell types with Ad-RSV/FRT2neo/ EGFP resulted in more Flp recombinase-mediated recombination and more EGFP-expressing cells (Figure 2b ).
To test whether Flp recombinase-mediated gene expression is responsive to activation of the PSA promoter by androgen, we infected LNCaP cells with Ad-PSA/FLP and Ad-RSV/FRT2neo/EGFP and cultured them in the presence and absence of the androgen R1881. In the absence of R1881, 17% of cells expressed EGFP. In contrast, in the presence of R1881, significantly more cells expressed EGFP (66%, Po0.01), an indication that the PSA promoter's responsiveness to androgen resulted in increased expression of Flp recombinase, which in turn resulted in B50% more expression of the EGFP reporter gene (Figure 2b and c) . Western analysis of protein extracts prepared from tumors 9 days after administration of different viral preparations confirmed that the fluorescence we observed in tumors was EGFP. We observed a 27 kDa 
PSA promoter-driven Flp recombinase-mediated recombination regulates gene expression following injection of virus to normal prostate and to prostate tumors
To test whether the PSA promoter effectively activates gene expression as a consequence of Flp recombinasemediated DNA recombination, we injected two viruses, Ad-PSA/FLP and Ad-RSV/FRT2neoLuc, directly into ventral lobes of mouse prostates. We used optical imaging to evaluate expression of luciferase in the prostates, 3 days following injection. We observed bioluminscence specifically in the ventral lobe, but not in other prostatic lobes (Figure 5a ).
When we injected the Ad-PSA/FLP and Ad-RSV/ FRT2neo/DT-A viruses directly into right ventral lobes of the prostates of mice, and observed the prostates 3 days later, we observed that the injected lobe was smaller than the uninjected ventral lobe. In control mice, injected with Ad-PSA/FLP and Ad-RSV/FRT2neo/Luc, both lobes were of the same size (Figure 5b ). The nearly complete ablation of lobes injected with the DT-A virus is consistent with our observations following treatment of cells in culture and of xenografts.
TUNEL analyses of sections of prostates from mice treated with the DT-A virus, the Luc control virus, and from nontreated mice are shown in Figure 5c . The percentage of TUNEL-positive cells in DT-A-treated prostates was significantly higher (Po0.01) than the percentage positive cells in Luc-treated prostates ( Figure  5d ). We also observed consistent changes in the cellular organization of the ventral prostate following viral treatment. In Luc control mice, there appeared to be proliferation of cells in the stromal compartment, while in the DT-A mice, the distinction between the epithelial and stromal compartments was lost. We next investigated whether virally delivered PSAregulated genes are expressed in autochthonous prostate tumors in TRAMP mice. These transgenic mice develop prostate tumors as a consequence of expression of SV40T and t antigens in the prostate. 6 We optically imaged mice and observed luciferase expression in the tumors 3 days following i.p. injection of Ad-PSA/FLP and Ad-RSV/ FRT2neo/Luc to TRAMP mice that had prostate tumors (Figure 6a) . To test the ability of virally-delivered PSA promoter-regulated DT-A to kill prostate tumor cells in TRAMP mice, we injected Ad-PSA/FLP and Ad-RSV/ FRT2neo/DT-A directly into tumors. Mice were euthanized and the prostates were processed 3 days after viral administration for TUNEL analysis. The percentage of TUNEL-positive cells in regions of tumors injected with the DT-A virus, presumably corresponding to the site of injection, was significantly higher (Po0.001) than comparable regions of control tumors injected with Luc virus and nontreated tumors (Figure 6b and c) .
Discussion
We used an adenoviral vector to deliver DNA sequences to cells in culture, to xenografts, and to autochthonous tumors in TRAMP mice, a transgenic mouse model for prostate cancer. Our studies show that viral delivery of DNA encoding Flp recombinase driven by a PSA promoter effectively regulates gene expression in a manner that correlates with the amount of PSA and androgen present in cells. Flp recombinase-mediated expression of DT-A in prostate cancer cells in culture, xenografts, and TRAMP mice resulted in the death of cells and/or the regression of tumors.
Identification of tissue and tumor-specific promoter elements for targeting expression of therapeutic and toxic genes to tumor cells is critically important for the practical application of gene therapy. 7, 8 Ideally, promoter elements should direct expression of the therapeutic DNA to tumor cells, and there should be no expression of the therapeutic DNA in normal, noncancerous cells. Since the absence of normal prostate function is not life threatening, therapeutic or toxic gene expression by normal prostate cells can be tolerated. Thus, compared to cancers in vital organs, gene therapy for the treatment of prostate cancer is an especially attractive option. In this study, we used a modified promoter/enhancer of the human PSA gene, PSE-BC, to regulate the expression of Flp recombinase. 5 PSA is expressed normally by secretory cells in the prostate. It is also expressed by prostate tumor cells in androgen-dependent and androgenindependent tumors as well as in androgen-independent metastatic foci. The PSE-BC promoter is active in the normal prostate and in prostate tumors in mice.
While many promoters have been identified that have high activity in one cell type as compared to others, these so-called 'cell-specific' promoters are usually 'leaky', that is, maintaining low-level activity in many different cell types. This minimal level of activity poses a problem when these promoters are used to regulate the expression of genes encoding highly toxic proteins such as DT-A (a single DT-A molecule is sufficient to kill a cell). 3 The bipartite Flp recombinase system that we have previously described 4 and use in this study requires expression of Flp recombinase at sufficient levels for efficient recombination to occur. This requirement effectively restricts DT-A expression to those cells where promoter activity is above basal level thereby helping to ensure that expression of the toxin is restricted to the targeted cells.
The observed increase in apoptotic cells in prostate tumors in TRAMP mice following intratumoral injection of adenoviruses housing PSA promoter/Flp recombinase and DT-A DNA constructs demonstrated effective gene Prostate cancer suicide gene therapy W Peng et al expression in tumors following viral delivery of genes tightly regulated by this dual system (transcription and DNA recombination). In an effort to determine whether DT-A expression resulted in regression in the size of authochthonous tumors, we used a microCAT scanner to image tumors before and after intratumoral viral injection. Three-dimensional (3-D) reconstructions of these images failed to show tumor regression. This is perhaps not surprising given the rapid growth of tumors in this model and the apparent restricted dissemination of virus following intratumoral injection. The dramatic reduction in size of the normal, nontumorigenic mouse prostate that we observed following intraprostatic injection of virus containing the DT-A construct strongly suggests that, under the proper conditions, DT-A therapy should effectively reduce tumor burden. In particular, the use of other transgenic mouse models with slower growing tumors that better reflect the growth of human prostate tumors, together with noninvasive imaging, would likely result in tumor cell death and a demonstrable reduction in tumor size.
Up to one-third of patients with localized prostate cancer who have undergone treatments with curative intent will develop recurrent tumors and metastases. 9, 10 The fact that nearly 60% of patients with recurrent metastatic prostate cancer die within 5 years of recurrence underscores the clear need for a more effective treatment for metastatic disease. 11 The results of our study demonstrate that the use of adenoviral vectors to locally deliver a tightly-regulated DT-encoding DNA effectively kills prostate tumor cells. Systemic delivery of targeted gene therapy holds great promise for improving the treatment of metastatic cancers.
Targeting cell death to specific cells throughout the body can perhaps best be accomplished by combining tightly regulated expression of a suicide gene with improved methods for targeting DNA delivery. Early on in our work, we discovered that the prostate-specific promoter, PSE-BC, has activity in 293 cells, most probably due to the proximity of viral enenhancer sequences. This activity obviated the use of a single DNA construct having an embedded Flp recombinase sequence, regulated by PSE-BC, because recombinationmediated DNA excision resulted in viruses housing recombined DNA. It was necessary to house elements of the binary system in two viruses as we have described in this report. Our studies serve as proof-of-principle that when the binary system is delivered efficiently to tumor cells, as it is with viral vectors, this approach effectively reduced the size of tumors. Recognizing that it would be economically impractical to administer two viruses to patients, and not as efficient as delivering DNA with one virus, we have been investigating the use of nonviral vectors for the delivery of a single 'Flp recombinase-embedded' DT-A DNA construct. We have recently shown that nanoparticles prepared with a new class of poly(b-amino ester) polymer can deliver DT-A DNA to prostate tumor cells, resulting in a retardation of tumor growth. 12 However, we were unable to effect a reduction in tumor size as we did here using viral vectors. The success we have achieved in this study using two viruses demonstrates that any vector capable of delivering a single DNA construct needs to attain the suboptimal efficiency of DNA delivery achieved with two viruses for effective therapeutic outcomes.
Modifications to vectors to improve targeted delivery will make it possible to achieve the required transduction efficiency.
The strategy applied in this study can be used with other so-called suicide genes. We chose to use DT-A for several reasons. Other suicide gene therapies, for example HSV-tk/ganciclovir 13 and cytosine deaminase/ 5-fluorocytosine, 14 benefit from a 'bystander effect', that is, the killing of untransfected cells localized next to transduced cells (see the review by Vassaux and MartinDuque 15 ). DT-A-based therapy, on the other hand, only kills transduced cells. This limitation makes transduction efficiency a challenge, but has the advantage that only cells that are specifically targeted are killed by the therapy. In addition, minimal DT-A expression is required. Another advantage of DT-A is that in contrast to other suicide genes that act by disrupting DNA synthesis, thereby targeting rapidly dividing cells, DT-A is a potent inhibitor of protein synthesis that acts in a cell cycle-independent fashion, killing both quiescent and rapidly dividing tumor cells. This property of DT-A adds to its attractiveness as a therapy for slow growing tumors like prostate tumors.
Suicide gene therapy for cancer can only be totally effective if all the cancer cells, including cancer stem cells, are killed. In reality, no vector, viral or nonviral, is likely to transduce 100% of tumor cells. Ultimately, the most effective therapeutic regimen for the treatment of advanced prostate cancer patients is likely to be a combination of a conventional treatment (ie, irradiation or surgery) targeting the primary tumor with a suicide gene therapy such as we describe here for targeting the death of metastatic lesions.
The fact that viral delivery of the Flp recombinase and DT-A DNA constructs directly into the normal mouse prostate resulted in a significant reduction in the size of the gland suggests that, in addition to its potential as a cancer therapy, this therapy may have clinical relevance for the treatment of benign prostatic hyperplasia (BPH). In contrast to drug-based therapies for BPH that are currently used to effect cytoreduction, targeted expression of DT-A would discriminate between PSA-expressing prostatic epithelial cells and other cell types (eg, nerve and muscle cells) found in close association with the periurethral prostate.
Materials and methods
Shuttle plasmids and virus production
To make the shuttle plasmid pPS/FLP, we first constructed pMECA-PSA/FLP. A 2-kb fragment, released by digestion of pOG-FLPe6 (gift of A Francis Stewart, EMBL, Heidelberg) with XbaI and SalI, was ligated to XbaI+XhoI-digested pMECA 16 to produce pMECA/ FLP(1). This plasmid was then digested with XbaI and AgeI to release a 2-kb fragment that was ligated to NheI+NgoMI digested pMECA to create pMECA/FLP(2). A 2.5-kb fragment, released from the plasmid pPSE-BC by digestion with XbaI and SalI, was ligated to XbaI+SalI-digested pMECA/FLP(2) to create pMECA-PSA/FLP. A 4.5-kb fragment released from pMECA-PSA/FLP by digestion with XbaI and AvrII, was ligated to XbaIdigested pDC312 (Microbix Biosystems, Inc., Toronto, Canada) to create pPSA/FLP. The shuttle plasmid pRSV/FRT2neo/lacZ was constructed as described. 4 The shuttle plasmid pRSV/FRT2neo/EGFP was constructed as follows. A 1.3-kb fragment containing FRT2neo (released by digestion with AgeI from the plasmid pFRT2neolacZ, a gift of Susan Dymecki) was inserted into the AgeI site of pRSV/EGFP to create pRSV/FRT2neo/EGFP. (To create pRSV/EGFP, a 1-kb fragment, released by digestion of pEGFP-1 (Clontech) with BamHI and AflII, was ligated to BamHI+AflII-digested pIND (Invitrogen) to produce pIND/EGFP. A 1-kb fragment, released from pIND/EGFP by digestion with SpeI and NheI, was then ligated to NheI-digested pDC312/RSV 4 to generate pRSV/EGFP.) The shuttle plasmid pRSV/FRT2neo/DT-A was constructed as follows. The plasmid p22EDT1 (gift of A Francis Stewart, EMBL, Heidelberg, Germany) was digested with BglII and NotI, releasing a 1.3-kb fragment that was ligated to a 5.0-kb fragment released from the plasmid pIND by BamHI+NotI digestion to create pIND/ DT-A. pIND/DT-A was digested with KpnI and XbaI, releasing a 1.3-kb fragment which was ligated to a KpnI+XbaI digest of pMECA 16 to create pMECA/DT-A. This plasmid was digested with AgeI and XbaI, releasing a 1.3-kb fragment which was ligated to a 3.8-kb fragment derived from an AgeI+NheI digest of pRSV/EGFP. The resulting plasmid, pRSV/DT-A, was digested with AgeI, and then ligated to a 1.3-kb fragment released by digestion with AgeI from the plasmid pFRT2neolacZ. Insert orientation was checked by digestion with XhoI.
The shuttle plasmid pRSV/FRT2neo/luc was constructed as follows. A 2.0-kb fragment, released from the pBCVP2G5-lucNSN (gift of Michael Carey, UCLA) by digestion with BglII and SalI, was ligated to (BglII+SalI)-digested pMECA to create pMECA/luc. This plasmid was digested with AgeI and SalI to release a 2.0-kb fragment that was ligated to AgeI+XhoI-digested pDC312-RSV/EGFP to create pDC312-RSV/luc. A 1.3-kb fragment, released from the plasmid pFRT2neolacZ by digestion with AgeI, was ligated into AgeI-digested pRSV/luc (see above) to generate pRSV/FRT2neo/luc.
The plasmid pCAG/luc was constructed as follows. A 1.2-kb fragment, released by digestion of phRL-null (Promega Corp., Madison, WI, USA) with BglII and XbaI, was ligated to BglII+XbaI digested pcDNA3.1 (Invitrogen, Carlsbad, CA, USA) to create pcDNA3.1/luc. The plasmid pCX-EGFP (gift of J Miyazaki, Kyoto U), was digested with SalI and EcoRI to release a 1.7-kb fragment. This fragment was ligated to a XhoI+EcoRI digest of pcDNA3.1/luc to produce pCAG/luc.
Ad-5 replication-defective viral vectors were prepared using the AdMax System (Microbix Biosystems, Inc., Toronto, Canada) as described 4 except that we used 293DTRP#2, a DT resistant adenoviral packaging line, rather than standard 293 cells.
Cells
PC-3 cells, purchased from the American Type Culture Collection (ATCC #1435), were maintained at 371C in 5% CO 2 , balance air, in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum. LNCaP cells (Urocor, Inc., Oklahoma City, OK, USA) were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum.
For experiments, cells were seeded at a density of 2 Â 10 4 cells per cm 2 in 24-well plates. After 48 h, cells were sequentially infected with two viruses (first with one virus, and 16 h later with the second virus). In some experiments, the culture medium contained 1 nM methyltrienolone (R1881) (Perkin-Elmer Life Sciences, Wellesley, MA, USA).
Reporter gene assays (Luciferase, EGFP)
We used the Luciferase Assay System (Promega, Madison, WI, USA) and a Monolight 2010 luminometer (Analytical Luminescence Laboratory, San Diego, CA, USA) to measure luciferase activity in cell extracts that were prepared according to the manufacturer's instructions. EGFP fluorescence was detected in cells and tumors using a Zeiss Axiovert 200 M inverted fluorescent microscope outfitted with a AxioCam MRm camera and Axiovision 4.0 software. Statistical comparison of the number of EGFP-expressing cells cultured in the presence and absence of R1881was made using an unpaired two-tailed Student's t-test.
Xenografts
We inoculated 2 Â 10 6 LNCaP cells in PBS and 20% Matrigel (Beckton Dickinson, Bedford, MA, USA) subcutaneously into each flank of 6-8-week-old nu/nu male mice (Harlan, Indianapolis, IN, USA). When tumors were approximately 250 mm 3 in size, we delivered virus to the tumors by intratumoral injection (10 10 viral particles of each virus). In some instances, as indicted in the text, the viral injection buffer contained 4 nM R1881 (Perkin-Elmer Life Sciences, Wellesley, MA, USA). In experiments with EGFP virus, tumors were excised and observed by fluorescent micrography at the indicated times. In experiments to assess tumor growth, we used calipers to measure the size of tumors before and after viral treatment. All measurements were made on intact mice. Statistical comparisons of tumor growth data were made using an unpaired two-tailed Student's t-test.
Western blot analysis
Tissues and tumors were homogenized in RIPA buffer and centrifuged at 12 000 r.p.m for 15 min at 41C. Protein concentration of extracts was determined using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Soluble proteins were separated by electrophoresis on 10% SDS-PAGE gels and analyzed by Western blotting. Filters were incubated with a mixture of primary antibodies, a polyclonal to EGFP (1:2000) (Clontech, Palo Alto, CA, USA) and a monoclonal to b-actin (1:20 000) (Sigma, clone AC-15), washed several times with PBST (phosphate buffered saline, 0.1% Tween), and then incubated in the dark with a mixture of secondary antibodies, Alexa 680-labeled goat anti-mouse (1:25 000) and IRD800-labeled goat anti-rabbit (1:10 000). After several washes in PBST and PBS, filters were scanned using an Odyssey Infrared Imager (Li-Cor, Inc., Lincoln, NE, USA). Fluorescent signals were visualized using Odyssey VI.1 software.
Bioluminescence imaging
Mice to be imaged were anesthesized with Avertin (5 mg/kg). Following i.p. administration of D-luciferin (150 mg/kg body weight; Xenogen, Inc., Alameda, CA, USA), mice were imaged for 1 min using an IVISt Prostate cancer suicide gene therapy W Peng et al bioluminescence imaging system (Xenogen, Inc., Alameda, CA, USA). When images from different mice were to be compared, care was taken to ensure that the same amount of time passed between the time of D-luciferin administration and the time at which the image was taken.
Apoptosis assay
After fixation in formalin for 2 h, tumors and prostates were processed for paraffin embedding. Apoptotic cells were identified in 5 mm sections by TUNEL assay using an In Situ Death Detection Kit (Roche Boehringer Mannheim, Indianapolis, IN, USA) according to the manufacturer's protocol. A Zeiss fluorescent microscope was used for the analysis of stained cells. Statistical comparison of the numbers of TUNEL positive cells treated with DT-A and LUC viruses treatment was made using an unpaired two-tailed Student's t-test.
Virus injection into normal prostate and prostate tumors
C57BL/6J mice (Jackson Laboratory) were anesthetized with Avertin (5 mg/kg) and a ventral abdominal incision was made to expose the prostate or tumor. Using a 30-gauge needle, a mixture of Ad-PSA/FLP (1.5 Â 10 10 particles) and Ad-RSV/FRT2neo/DT-A (or Luc) (1.2 Â 10 9 particles) in a 10 ml volume was injected directly into the right ventral lobe of the prostate or the tumor. The incision was closed with stiches and surgical clips. Upon killing of mice 3 days after injection of viruses, tumors and prostates were fixed and processed for TUNEL assay.
